Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G6EB
|
|||
| Former ID |
DIB001870
|
|||
| Drug Name |
MDX-1097
|
|||
| Synonyms |
CKap; MKap; K-1-21; Mab therapy, Immune System therapeutics/Medarex; Monoclonal antibody (multiple myeloma, humanized/murine/chimeric), PacMab/Medarex
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 2 | [1] | |
| Company |
Immune System Therapeutics Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Kappa myeloma antigen (KMA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025289) | |||
| REF 2 | MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol. 2015 May;169(3):333-43. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.